Summit Therapeutics PLC (SMMT)

Currency in USD
26.290
+0.090(+0.34%)
Closed·
26.200-0.070(-0.27%)
·
SMMT Scorecard
Full Analysis
Suffers from weak gross profit margins
SMMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.99026.490
52 wk Range
11.76036.910
Key Statistics
Prev. Close
26.2
Open
26.2
Day's Range
25.99-26.49
52 wk Range
11.76-36.91
Volume
2.02M
Average Volume (3m)
3.88M
1-Year Change
100.31%
Book Value / Share
0.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SMMT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.320
Upside
+26.74%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Summit Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Summit Therapeutics PLC Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics PLC Earnings Call Summary for Q1/2025

  • Summit Therapeutics beats Q1 2025 EPS forecast with -$0.07 vs -$0.09 expected, stock rises 2.28% to $24.64 in aftermarket trading
  • Company maintains strong cash position of $361 million with no debt, excellent liquidity ratio of 10.15 bolsters investor confidence
  • Positive clinical trial results and product approvals drive optimism, with lead asset Ivanismab showing significant advancements
  • GAAP R&D expenses flat at $51.2 million, G&A expenses up to $15.6 million; company expects HARMONY trial top-line data in mid-2025
  • Executives emphasize mission-driven approach and strategic focus on accelerating development of cancer therapies beyond lung cancer
Last Updated: 01/05/2025, 23:02
Read Full Transcript

Compare SMMT to Peers and Sector

Metrics to compare
SMMT
Peers
Sector
Relationship
P/E Ratio
−26.2x−2.4x−0.6x
PEG Ratio
0.080.020.00
Price/Book
75.3x1.1x2.6x
Price / LTM Sales
-54.6x3.3x
Upside (Analyst Target)
33.1%246.2%37.4%
Fair Value Upside
Unlock23.2%4.5%Unlock

Analyst Ratings

11 Buy
1 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.320
(+26.74% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-0.12 / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SMMT Income Statement

People Also Watch

49.55
BMNR
-7.38%
72.31
MP
+6.53%
35.900
SMR
+2.45%
15.020
QBTS
-3.35%
125.24
CRCL
-7.26%

FAQ

What Stock Exchange Does Summit Therapeutics PLC Trade On?

Summit Therapeutics PLC is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Summit Therapeutics PLC?

The stock symbol for Summit Therapeutics PLC is "SMMT."

What Is the Summit Therapeutics PLC Market Cap?

As of today, Summit Therapeutics PLC market cap is 19.83B.

What Is Summit Therapeutics PLC's Earnings Per Share (TTM)?

The Summit Therapeutics PLC EPS (TTM) is -1.01.

When Is the Next Summit Therapeutics PLC Earnings Date?

Summit Therapeutics PLC will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is SMMT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Summit Therapeutics PLC Stock Split?

Summit Therapeutics PLC has split 0 times.

How Many Employees Does Summit Therapeutics PLC Have?

Summit Therapeutics PLC has 159 employees.

What is the current trading status of Summit Therapeutics PLC (SMMT)?

As of 25 Aug 2025, Summit Therapeutics PLC (SMMT) is trading at a price of 26.29, with a previous close of 26.20. The stock has fluctuated within a day range of 25.99 to 26.49, while its 52-week range spans from 11.76 to 36.91.

What Is Summit Therapeutics PLC (SMMT) Price Target According to Analysts?

The average 12-month price target for Summit Therapeutics PLC is USD33.31970004, with a high estimate of USD43.90352655 and a low estimate of USD12.09160924. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +26.74% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.